Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
2022年5月10日 - 9:00PM
ビジネスワイヤ(英語)
- Environmental, Social and Governance (ESG) efforts integrated
into business strategy with strengthened oversight, robust targets
and sustainability-linked bond (SLB)
- Progress toward targets to improve access to medicines,
including launch of four programs to-date (50% of 2025 target) and
minimize environmental impact, with 13% reduction of scope 1 and 2
greenhouse gas (GHG) emissions (more than 50% of 2025 target)
- New disclosures on scope 3 GHG emissions, pay equity and
responsible supply chain as well as three new position
statements
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a
leading global pharmaceutical company providing medicines to nearly
200 million people daily, published its 2021 ESG Progress
Report today. The report details how Teva further integrated
ESG into its business strategy—implementing a strengthened ESG
governance structure and setting 13 ambitious targets related to
access to medicines, ethics, environment and responsible supply
chain, some of which are now linked to the company’s financing
strategy and executive compensation.
“As one of the world's largest manufacturers of generic
medicines, ESG is integral to the long-term strategy of our company
and is part of everything we do," said Kåre Schultz, President
& CEO of Teva. “Our ESG Progress Report details our actions in
2021, which include issuing a $5 billion sustainability-linked
bond, tying our financing strategy to access to medicines and
environmental targets. We are in a unique position to help create a
healthier future, bringing our essential medicines within reach for
more people and reinforcing business integrity through our
compliance and ethics policies and trainings.”
This year’s ESG Progress Report offers a comprehensive view of
ESG at Teva, with new disclosures related to scope 3 emissions, pay
equity and the company’s responsible supply chain, and continues to
align with leading reporting standards—the Global Reporting
Initiative (GRI), Sustainability Accounting Standards Board (SASB)
and Task Force on Climate-Related Financial Disclosures (TCFD).
The ESG Progress Report shares Teva’s progress, including:
- Integrating ESG further into the business with a $5 billion
sustainability-linked bond (SLB): Upon issuance, Teva’s SLB was
the largest in the world, the first in the pharmaceutical industry
linked to both social and environmental targets and the first from
a generic medicines company. The SLB holds Teva accountable to
reducing scope 1 and 2 GHG emissions by 25% and increasing access
to essential medicines for patients in low- and middle-income
countries (LMICs) by 150% by the end of 2025.
- Making medicines available and accessible to those who need
them: Teva has launched four access to medicines programs
to-date, 50% of its 2025 target, including an expanded partnership
with Direct Relief and Global HOPE to provide critical treatments
for children with cancer and blood disorders across sub-Saharan
Africa and new programs in France, Israel and Ghana. Last year, the
company also had 585 marketing authorizations approved in LMICs and
donated more than $487 million worth of medicines.
- Minimizing environmental impact across Teva's business and
value chain: Since 2019, Teva has reduced its scope 1 and 2 GHG
emissions by 13%, more than half of its 2025 target. Since 2020,
the company also reduced its scope 3 GHG emissions by 5% (20% of
2030 target), increased its total proportion of energy from
renewable sources by 4% (to 33%) and improved energy efficiency by
6%. In this same timeframe, it achieved an 8% reduction in both
waste from operations and water withdrawal in areas projected to be
in water stress.
- Fostering an inclusive workplace: Last year, the
representation of women in executive and senior management
positions at Teva increased by 1.8%. The company also trained
nearly 90% of employees on how to foster an inclusive culture.
- Promoting ethics and operating with integrity: Teva
trained more than 20,000 employees (99.6% of those assigned) on
ethics. The company published three new position statements
outlining its stance on patient safety, responsible supply chain
and risk management. Teva was also ranked in the top 1% in the
EcoVadis sustainable procurement assessment as a result of its
efforts to make more responsible decisions regarding supply chain
partners.
Teva’s ESG performance continues to improve across key rating
indices—including S&P Global, ISS ESG, EcoVadis and
FTSE4Good—which listed Teva among the top 10-20% of companies in
its industry in 2021.
Learn more about Teva’s ESG journey in the full 2021 ESG
Progress Report.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic and specialty medicines with a portfolio consisting of over
3,500 products in nearly every therapeutic area. Nearly 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management’s current beliefs and expectations
and are subject to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or
achievements to differ significantly from that expressed or implied
by such forward-looking statements. Important factors that could
cause or contribute to such differences include risks relating
to:
- our ability to impact and effectively execute on our social,
economic, environment and governance related strategies and goals;
environmental risks; failure to comply with applicable
environmental laws and regulations worldwide; our ability to
satisfy the targets set forth in our sustainability-linked senior
notes and in other sustainability-linked financing instruments that
we may issue; the impact of ESG issues on our business; and
consequences of climate change;
- our ability to successfully compete in the marketplace,
including: that we are substantially dependent on our generic
products; consolidation of our customer base and commercial
alliances among our customers; delays in launches of new generic
products; the increase in the number of competitors targeting
generic opportunities and seeking U.S. market exclusivity for
generic versions of significant products; our ability to develop
and commercialize biopharmaceutical products; competition for our
specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our
ability to achieve expected results from investments in our product
pipeline; our ability to develop and commercialize additional
pharmaceutical products; and the effectiveness of our patents and
other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to
incur additional indebtedness, engage in additional transactions or
make new investments, may result in a further downgrade of our
credit ratings; and our inability to raise debt or borrow funds in
amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty
regarding the COVID-19 pandemic and the governmental and societal
responses thereto; our ability to successfully execute and maintain
the activities and efforts related to the measures we have taken or
may take in response to the COVID-19 pandemic and associated costs
therewith; effectiveness of our optimization efforts; our ability
to attract, hire and retain highly skilled personnel; manufacturing
or quality control problems; interruptions in our supply chain;
disruptions of information technology systems; breaches of our data
security; variations in intellectual property laws; challenges
associated with conducting business globally, including political
or economic instability, major hostilities or terrorism; costs and
delays resulting from the extensive pharmaceutical regulation to
which we are subject or delays in governmental processing time due
to travel and work restrictions caused by the COVID-19 pandemic;
the effects of reforms in healthcare regulation and reductions in
pharmaceutical pricing, reimbursement and coverage; significant
sales to a limited number of customers; our ability to successfully
bid for suitable acquisition targets or licensing opportunities, or
to consummate and integrate acquisitions; and our prospects and
opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including:
failure to comply with complex legal and regulatory environments;
increased legal and regulatory action in connection with public
concern over the abuse of opioid medications and our ability to
reach a final resolution of the remaining opioid-related
litigation; scrutiny from competition and pricing authorities
around the world, including our ability to successfully defend
against the U.S. Department of Justice criminal charges of Sherman
Act violations; potential liability for patent infringement;
product liability claims; failure to comply with complex Medicare
and Medicaid reporting and payment obligations; and compliance with
anti-corruption sanctions and trade control laws;
- other financial and economic risks, including: our exposure to
currency fluctuations and restrictions as well as credit risks;
potential impairments of our intangible assets; potential
significant increases in tax liabilities (including as a result of
potential tax reform in the United States); and the effect on our
overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business;
and other factors discussed in our Quarterly Report on Form 10-Q
for the first quarter of 2022 and in our Annual Report on Form 10-K
for the year ended December 31, 2021, including in the sections
captioned “Risk Factors” and “Forward-Looking Statements” and in
our other reports that we file with the U.S. Securities and
Exchange Commission. Forward-looking statements speak only as of
the date on which they are made, and we assume no obligation to
update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220510005150/en/
IR Contacts Ran Meir (267) 468-4475 Yael Ashman +972 (3)
914 8262 PR Contacts Kelley Dougherty (973) 832-2810 Eden
Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 8 2024 まで 9 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 9 2023 まで 9 2024